Biopharma Investing With Avisol Capital: A Careful Balance Of Rules, Instincts (Podcast) [Seeking Alpha]
Last amarin corp plc ads earnings: 4/30 05:00 am
Check Earnings Report
US:NASDAQ Investor Relations: investor.amarincorp.com/investors
Biopharma Investing With Avisol Capital: A Careful Balance Of Rules, Instincts (Podcast) Summary Dr. Ashok Dutta of Avisol Capital discusses his methods for picking biopharma stocks. The firm generally invests in companies whose drugs have passed Phase 2 trials and exists once its drug enters the market. Right now Avisol is bullish on , , VKTS, . Lessons include a careful balance of rules-based investing with "smart improvisations" based on instincts honed by decades of experience. More Marketplace Roundtable Podcasts » Listen and subscribe to the Marketplace Roundtable on these podcast platforms: By Nathaniel E. Baker Avisol Capital Partners The Total Pharma Tracker Avisol has two styles: On the one hand a long-term buy and hold strategy with active monitoring and profit taking. On the other, a non-algorithmic, short-term momentum trading model supported by fundamental data and catalyst. "We believe in moderate risk taking," says Dutta. Avisol never invests in companies that do no
[Read more]
| Impact snapshot | Event time: | AMRN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
AMRN alerts
AMRN alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMRN alerts
High impacting Amarin Corp Plc ADS news events
Weekly update
A roundup of the hottest topics
AMRN
News
- Amarin to Report Second Quarter and Six Month 2021 Financial Results and Host Conference Call on August 5, 2021GlobeNewswire
- Pharmaceutical Executive® APEX Awards Announces 2021 FinalistsPR Newswire
- Amarin Co. plc (<a href="https://www.marketbeat.com/stocks/NASDAQ/AMRN/price-target/">NASDAQ: AMRN</a>) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $5.50 price targMarketBeat
- U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents [Financial Post (Toronto, Ontario, Canada)]Financial Post
- U.S. Supreme Court denies Amarin's bid to revive Vascepa drug patents [Financial Post (Toronto, Ontario, Canada)]Financial Post
- More
AMRN
SEC Filings
- 7/2/21 - Form 4
- 7/2/21 - Form 4
- 7/2/21 - Form 4
- AMRN's page on the SEC website
- More